Zai Lab to Unveil Early Clinical Data for Bispecific Antibody…

Event summary

Zai Lab will present first-in-human clinical trial data for ZL-1503, an IL-13/IL-31Rα bispecific antibody, at ACAAI 2026 on November 13, 2026.
The Phase 1/1b trial (NCT07235384) evaluated single-dose administration in healthy volunteers, with results including pharmacokinetic, pharmacodynamic, safety, and immunogenicity data.
ZL-1503 targets atopic dermatitis and other IL-13- and IL-31-driven diseases, aiming to disrupt the itch-scratch-inflammation cycle.
Preclinical data showed rapid itch relief and significant inflammation reduction in animal models.

The big picture

Zai Lab's presentation of ZL-1503 data at ACAAI 2026 marks a critical milestone in the development of a potentially first-in-class treatment for atopic dermatitis. The bispecific antibody approach targets two key cytokines involved in the disease, offering a novel therapeutic strategy. Success in early trials could position ZL-1503 as a significant player in the immunology market, which continues to see high demand for innovative treatments addressing unmet needs in inflammatory and autoimmune conditions.

What we're watching

Clinical Efficacy: How the Phase 1/1b data will position ZL-1503 against existing treatments for atopic dermatitis and other IL-13/IL-31-driven diseases.
Regulatory Pathway: The pace at which Zai Lab can advance ZL-1503 into later-stage trials and potential regulatory approvals.
Market Differentiation: Whether ZL-1503's bispecific mechanism can offer a sustained competitive advantage in the crowded immunology space.